Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)
2.250
-0.010 (-0.44%)
Mar 28, 2025, 4:45 PM SGT
SGX:T14 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Operating Revenue | 7,307 | 8,206 | 8,231 | 6,892 | 6,590 | Upgrade
|
Other Revenue | - | 16.23 | 17.87 | 15.33 | 13.64 | Upgrade
|
Revenue | 7,307 | 8,222 | 8,249 | 6,908 | 6,604 | Upgrade
|
Revenue Growth (YoY) | -11.13% | -0.33% | 19.42% | 4.60% | -5.58% | Upgrade
|
Cost of Revenue | 3,786 | 4,632 | 4,992 | 4,161 | 4,024 | Upgrade
|
Gross Profit | 3,521 | 3,590 | 3,258 | 2,747 | 2,580 | Upgrade
|
Selling, General & Admin | 2,459 | 2,508 | 2,347 | 1,930 | 1,815 | Upgrade
|
Research & Development | 162.38 | 184.63 | 153.15 | 161.05 | 149.2 | Upgrade
|
Other Operating Expenses | 44.61 | 79.05 | 76.69 | 64.12 | 58.29 | Upgrade
|
Operating Expenses | 2,666 | 2,791 | 2,586 | 2,160 | 2,029 | Upgrade
|
Operating Income | 855.21 | 799.27 | 671.32 | 587.04 | 551.04 | Upgrade
|
Interest Expense | - | -35.85 | -10.27 | -2.94 | -0.01 | Upgrade
|
Interest & Investment Income | 1,908 | 362.75 | 330.35 | 263.97 | 188.48 | Upgrade
|
Currency Exchange Gain (Loss) | - | -1.13 | -2.44 | 0.69 | 1.73 | Upgrade
|
Other Non Operating Income (Expenses) | -53 | -1.73 | 3.63 | -5.3 | -6.27 | Upgrade
|
EBT Excluding Unusual Items | 2,710 | 1,123 | 992.59 | 843.46 | 734.98 | Upgrade
|
Impairment of Goodwill | - | -18.78 | -19.57 | - | - | Upgrade
|
Gain (Loss) on Sale of Assets | 0.11 | -0.48 | 0.67 | 10.39 | 6.62 | Upgrade
|
Asset Writedown | -131.32 | -24.95 | -0.18 | - | - | Upgrade
|
Other Unusual Items | - | 16.27 | 6.67 | 18.96 | 26.46 | Upgrade
|
Pretax Income | 2,579 | 1,095 | 980.19 | 872.81 | 768.06 | Upgrade
|
Income Tax Expense | 363.56 | 126.66 | 106.93 | 85.93 | 88.4 | Upgrade
|
Earnings From Continuing Operations | 2,215 | 968.71 | 873.26 | 786.88 | 679.66 | Upgrade
|
Minority Interest in Earnings | 14.12 | 18 | -11.46 | -17.73 | -17.96 | Upgrade
|
Net Income | 2,229 | 986.71 | 861.79 | 769.14 | 661.7 | Upgrade
|
Net Income to Common | 2,229 | 986.71 | 861.79 | 769.14 | 661.7 | Upgrade
|
Net Income Growth | 125.94% | 14.49% | 12.05% | 16.24% | 5.78% | Upgrade
|
Shares Outstanding (Basic) | 769 | 771 | 769 | 769 | 769 | Upgrade
|
Shares Outstanding (Diluted) | 771 | 771 | 776 | 769 | 769 | Upgrade
|
Shares Change (YoY) | 0.07% | -0.71% | 0.94% | -0.04% | -0.37% | Upgrade
|
EPS (Basic) | 2.90 | 1.28 | 1.12 | 1.00 | 0.86 | Upgrade
|
EPS (Diluted) | 2.89 | 1.28 | 1.11 | 1.00 | 0.86 | Upgrade
|
EPS Growth | 125.78% | 15.32% | 11.00% | 16.28% | 6.17% | Upgrade
|
Free Cash Flow | 806.86 | 547.56 | 569.34 | 695.45 | 482.26 | Upgrade
|
Free Cash Flow Per Share | 1.05 | 0.71 | 0.73 | 0.90 | 0.63 | Upgrade
|
Dividend Per Share | - | 1.280 | 1.120 | 0.500 | 0.300 | Upgrade
|
Dividend Growth | - | 14.29% | 124.00% | 66.67% | - | Upgrade
|
Gross Margin | 48.19% | 43.66% | 39.49% | 39.77% | 39.07% | Upgrade
|
Operating Margin | 11.70% | 9.72% | 8.14% | 8.50% | 8.34% | Upgrade
|
Profit Margin | 30.51% | 12.00% | 10.45% | 11.13% | 10.02% | Upgrade
|
Free Cash Flow Margin | 11.04% | 6.66% | 6.90% | 10.07% | 7.30% | Upgrade
|
EBITDA | 976.73 | 923.54 | 786.15 | 701.29 | 660.9 | Upgrade
|
EBITDA Margin | 13.37% | 11.23% | 9.53% | 10.15% | 10.01% | Upgrade
|
D&A For EBITDA | 121.52 | 124.27 | 114.83 | 114.25 | 109.85 | Upgrade
|
EBIT | 855.21 | 799.27 | 671.32 | 587.04 | 551.04 | Upgrade
|
EBIT Margin | 11.70% | 9.72% | 8.14% | 8.50% | 8.34% | Upgrade
|
Effective Tax Rate | 14.10% | 11.56% | 10.91% | 9.84% | 11.51% | Upgrade
|
Revenue as Reported | - | 8,222 | 8,249 | 6,908 | 6,604 | Upgrade
|
Advertising Expenses | - | - | - | 321.16 | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.